

What is claimed is:

1. A compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding KOX 1, wherein said compound specifically hybridizes with said nucleic acid molecule encoding KOX 1 and inhibits the expression of KOX 1.
2. The compound of claim 1 which is an antisense oligonucleotide.
3. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
4. The compound of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage.
5. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
6. The compound of claim 5 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
7. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
8. The compound of claim 7 wherein the modified nucleobase is a 5-methylcytosine.
9. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
10. A compound 8 to 80 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of a preferred target region on a nucleic acid molecule encoding KOX 1.
11. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
12. The composition of claim 11 further comprising a colloidal dispersion system.
13. The composition of claim 11 wherein the compound is an antisense oligonucleotide.

14. A method of inhibiting the expression of KOX 1 in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of KOX 1 is inhibited.

15. A method of treating an animal having a disease or condition associated with KOX 1 comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of KOX 1 is inhibited.

16. The method of claim 15 wherein the disease or condition is a hyperproliferative disorder.

17. The method of claim 16 wherein the hyperproliferative disorder is cancer.

18. The method of claim 15 wherein the disease or condition arises from viral or bacterial infection.

19. The method of claim 15 wherein the disease or condition involves hyperactivation of an immune response.

20. A method of screening for an antisense compound, the method comprising the steps of:

- a. contacting a preferred target region of a nucleic acid molecule encoding KOX 1 with one or more candidate antisense compounds, said candidate antisense compounds comprising at least an 8-nucleobase portion which is complementary to said preferred target region, and
- b. selecting for one or more candidate antisense compounds which inhibit the expression of a nucleic acid molecule encoding KOX 1.